ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIRO..CY..TRBGCZEEHUPLSK....IS..MT..........................*JDIM360 Ver 2.41 (21 Oct 2013) - 2999001/02054074CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120141112W173deBibliographieenBibliographyfrBibliographieEP07812992.1200707162009022520100322enenen835429 P20060804US2014111220144620090506200919201410012014402014052820141112201446C07K 14/505 20060101AFI20140508BHEP A61K 38/00 20060101ALI20140508BHEP deMODIFIZIERTES ERYTHROPOIETINenMODIFIED ERYTHROPOIETINfrERYTHROPOÏÉTINE MODIFIÉEEP-A- 1 333 036WO-A-2004/091494WO-A1-2004/009627WO-A2-02/49673WO-A2-03/029291WO-A2-2006/089228US-A1- 2004 266 690US-A1- 2004 266 690US-A1- 2005 147 661US-A1- 2005 159 353LONG D L ET AL: "Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 34, no. 6, 1 June 2006 (2006-06-01), pages 697-704, XP025017483, ISSN: 0301-472X, DOI: DOI:10.1016/J.EXPHEM.2006.02.011 [retrieved on 2006-06-01]20091119ABUCHOWSKI, Abraham62 Bunnvale RoadCalifon, NJ 07830USLEE, Lihysyng Stanford109 Einstein WayCranbury, New Jersey 08512USProlong Pharmaceuticals, LLC101478462132 928 a/scho300B Corporate CourtSouth Plainfield, NJ 07080USHoffmann Eitle100061036Patent- und Rechtsanwälte PartmbB Arabellastraße 3081925 MünchenDEATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEISITLILTLULVMCMTNLPLPTROSESISKTRUS200707362920070716enWO20080192142008021420080720090506200919